Добірка наукової літератури з теми "Pregnancy BP"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Pregnancy BP".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Pregnancy BP"
1
Slater, Kaylee, Niamh Chapman, and Dean Picone. "O29 LACK OF VALIDATED BLOOD PRESSURE DEVICES FOR USE IN PREGNANCY AVAILABLE FROM AUSTRALIAN PHARMACIES." Journal of Hypertension 42, Suppl 3 (September 2024): e14. http://dx.doi.org/10.1097/01.hjh.0001062580.31122.e4.
Повний текст джерелаАнотація:
Background and objective. Self-monitoring of blood pressure (BP) at home can aid in the management of hypertension, including during pregnancy. Only 20% of home BP devices have been validated for the general population. However, specific accuracy validation in pregnant women is required for use among this population. The availability of home BP devices that have been validated for use in pregnant women is unknown, which was the aim of this study. Secondary aims were to assess device cost and claims regarding use in pregnancy. Methods. A search of pharmacies with physical and online stores in Australia that sell upper-arm cuff home BP devices was conducted. Validation status in pregnant women was determined by checking model numbers on the STRIDE-BP website. Cost of device and claims about the devices’ use in pregnancy were extracted from instruction manuals and information on the pharmacy webpage. Results. Eighteen pharmacies and 40 unique home BP devices were identified. Four (10%) devices were validated for use in pregnancy, and these were more expensive than other devices (Table). Fifteen devices listed a caution warning to seek healthcare provider advice before use if pregnant, including all four that had been validated for pregnancy. Concerningly, information about four devices stated they were recommended for pregnancy, although evidence of validation was not found on STRIDE-BP. Information about one device stated it had not been tested on pregnant women and was not suitable for use, although this information was only available in the device manual and not point-of-sale. Nineteen devices had no mention of pregnancy at all. Conclusion. Very few home BP devices available from Australian pharmacies are specifically validated for use in pregnancy, are priced higher than non-validated devices and do not effectively target their intended users. To guarantee that only validated home BP devices are used in pregnancy increased awareness is urgently needed and could be assisted by clear labelling on devices provided at the point-of-sale instore or online. Table. Home BP devices sold in 18 Australian pharmacies. BP: blood pressure. Cost displayed in Australian dollars (AUD). The percentages add to more than 100% because some devices validated in the general population were also validated for pregnancy and pre-eclampsia.
2
VASILIEV, S. A., S. A. VIKTOR, T. P. VASHCHILINA, E. V. KOVALKOVA, J. K. AVER, and J. L. SEGEN. "HEMODYNAMIC PARAMETERS IN WOMEN WITH HYPERTENSIVE DISORDERS DURING PREGNANCY." MODERN PERINATAL MEDICAL TECHNOLOGIES IN SOLVING THE PROBLEM OF DEMOGRAPHIC SECURITY, no. 17 (December 2024): 22–29. https://doi.org/10.63030/2307-4795/2024.17.a.03.
Повний текст джерелаАнотація:
Аn analysis of blood pressure (hereinafter referred to as BP) and derived hemodynamic parameters was performed in women with hypertension that existed previously (n=40) or was caused by pregnancy (n=40) and 30 women without hypertensive disorders during pregnancy. It was established that at the stage of pre-pregnancy preparation and during pregnancy, the recommended values of office and home BP should be in the range of optimal BP values according to the modern classification of BP threshold values for optimal, elevated pressure and hypertension (ESH, 2024). Blood pressure corresponding to elevated pressure (120/70 mm Hg and higher) should be considered as a risk factor for the development of hypertensive disorders during pregnancy.
3
Zhang, Yu, Juxiao Li, Jiaqiang Liao, Chen Hu, Zhongqiang Cao, Wei Xia, Shunqing Xu, and Yuanyuan Li. "Impacts of Ambient Fine Particulate Matter on Blood Pressure Pattern and Hypertensive Disorders of Pregnancy." Hypertension 77, no. 4 (April 2021): 1133–40. http://dx.doi.org/10.1161/hypertensionaha.120.15608.
Повний текст джерелаАнотація:
Ambient fine particulate matter (PM 2.5 ) exposure during pregnancy was associated with hypertensive disorders of pregnancy (HDP) in previous studies, however, the results were inconsistent. In addition, its effects on blood pressure (BP) pattern, which was different between normal pregnancy and pregnancy with HDP, remain unclear. In this study, we estimate daily PM 2.5 exposure levels of 7658 pregnant women from a prospective cohort study in Wuhan, China, using land use regression model. BP was repeatedly measured in each trimester. Linear mixed-effect model was used to examine associations of PM 2.5 exposure with BP patterns during pregnancy. The association between PM 2.5 exposure and HDP was estimated by modified Poisson regression. In the lowest quartile of PM 2.5 exposure, BP fell gradually during early pregnancy and increase subsequently after a nadir at mid-pregnancy. In higher quartiles of PM 2.5 exposure, a slower drop of BP was observed during early pregnancy, and the mid-pregnancy drop was less obvious compared with the lowest quartile. PM 2.5 exposure during the second trimester was positively associated with the risk of HDP (relative risk =1.42 [95% CI, 1.19–1.70]), especially among women with excessive gestational weight gain (relative risk =1.48 [95% CI, 1.16–1.90; P for interaction =0.03). Our study suggests that PM 2.5 exposure might play an important role in BP pattern during pregnancy and might increase the risk of HDP, especially among women with excessive gestational weight gain.
4
Jacobs, Brandiese E., Yong Liu, Maria V. Pulina, Vera A. Golovina, and John M. Hamlyn. "Normal pregnancy: mechanisms underlying the paradox of a ouabain-resistant state with elevated endogenous ouabain, suppressed arterial sodium calcium exchange, and low blood pressure." American Journal of Physiology-Heart and Circulatory Physiology 302, no. 6 (March 15, 2012): H1317—H1329. http://dx.doi.org/10.1152/ajpheart.00532.2011.
Повний текст джерелаАнотація:
Endogenous cardiotonic steroids (CTS) raise blood pressure (BP) via vascular sodium calcium exchange (NCX1.3) and transient receptor-operated channels (TRPCs). Circulating CTS are superelevated in pregnancy-induced hypertension and preeclampsia. However, their significance in normal pregnancy, where BP is low, is paradoxical. Here we test the hypothesis that vascular resistance to endogenous ouabain (EO) develops in normal pregnancy and is mediated by reduced expression of NCX1.3 and TRPCs. We determined plasma and adrenal levels of EO and the impact of exogenous ouabain in pregnancy on arterial expression of Na+ pumps, NCX1.3, TRPC3, and TRPC6 and BP. Pregnant (embryonic day 4) and nonpregnant rats received infusions of ouabain or vehicle. At 14–16 days, tissues and plasma were collected for blotting and EO assay by radioimmunoassay (RIA), liquid chromatography (LC)-RIA, and LC-multidimensional mass spectrometry (MS3). BP (−8 mmHg; P < 0.05) and NCX1.3 expression fell (aorta −60% and mesenteric artery −30%; P < 0.001) in pregnancy while TRPC expression was unchanged. Circulating EO increased (1.14 ± 0.13 nM) vs. nonpregnant (0.6 ± 0.08 nM; P < 0.05) and was confirmed by LC-MS3 and LC-RIA. LC-MS3 revealed two previously unknown isomers of EO; one increased ∼90-fold in pregnancy. Adrenal EO but not isomers were increased in pregnancy. In nonpregnant rats, similar infusions of ouabain raised BP (+24 ± 3 mmHg; P < 0.001). In ouabain-infused rats, impaired fetal and placental growth occurred with no BP increase. In summary, normal pregnancy is an ouabain-resistant state associated with low BP, elevated circulating levels of EO, two novel steroidal EO isomers, and increased adrenal mass and EO content. Ouabain raises BP only in nonpregnant animals. Vascular resistance to the chronic pressor activity of endogenous and exogenous ouabain is mediated by suppressed NCX1.3 and reduced sensitivity of events downstream of Ca2+ entry. The mechanisms of EO resistance and the impaired fetal and placental growth due to elevated ouabain may be important in pregnancy-induced hypertension (PIH) and preeclampsia (PE).
5
Menti, Ariadni, Dimitrios Mariglis, Konstantinos Kyriakoulis, Anastasios Kollias, Paolo Palatini, Gianfranco Parati, Jiguang Wang, Aletta Schutte, and George Stergiou. "O32 AVAILABILITY OF PROPERLY VALIDATED BLOOD PRESSURE MEASURING DEVICES FOR PREGNANT WOMEN: STRIDE BP SYSTEMATIC REVIEW." Journal of Hypertension 42, Suppl 3 (September 2024): e15. http://dx.doi.org/10.1097/01.hjh.0001062592.89400.1e.
Повний текст джерелаАнотація:
Background and Objective: Validated automated upper-arm cuff blood pressure (BP) measuring devices are currently recommended for BP measurement. However, a validated BP device in the general population may be inaccurate in pregnant women. Thus, separate validation studies are required in pregnant women with normal BP, hypertension, and preeclampsia. This study assessed the published evidence on BP devices in pregnancy. Methods: STRIDE BP (www.stridebp.org) performs periodic systematic PubMed searches to identify validation studies of automated cuff BP monitors. Validation studies in pregnancy conducted using an established protocol, including the AAMI/ESH/ISO Universal Standard (ISO 81060-2:2018), ANSI/AAMI/ISO 2013/2009, ESH-IP 2010/2002, AAMI 2002/1992/1987, and BHS 1993/1990, were identified. Results: Of 569 validation studies included in the STRIDE BP database, 63 (35 devices) were identified including pregnant women. Among them, STRIDE BP rejected 45 studies, of which 25 were reported as “device pass” in the published validation paper. Among the studies rejected by STRIDE BP but published as “pass”, the main reasons for rejection were violations in the BP measurement protocol (44%), inadequate reference device or cuffs for reference and test device (36%), no data in women with hypertension and/or preeclampsia (36%), single observer for reference BP measurement (28%), and inappropriate data analysis (20%). Eventually 18 studies in pregnant women (28.6%) fulfilled the protocol requirements, and 16 devices (8 of them available on the market) can be recommended for clinical use in pregnancy. When additional ‘equivalent’ devices were considered (devices lacking validation studies but with differences from validated devices not affecting the BP measurement accuracy), 37 devices were found to be accurate in pregnancy, with 27 of them available on the market (Table). Conclusions: This analysis showed a shortage of properly validated BP devices for pregnant women available in the market, with published validation often having major methodological issues. There is an urgent need to develop and properly validate more BP devices in pregnancy. TABLE. Validated devices for office, home, and ambulatory BP measurement in pregnant women.
6
Dunietz, Galit Levi, Wei Hao, Kerby Shedden, Claudia Holzman, Ronald Chervin, Lynda Lisabeth, Marjorie Treadwell, and Louise O’Brien. "470 Maternal Habitual Snoring and Blood Pressure Trajectories in Pregnancy." Sleep 44, Supplement_2 (May 1, 2021): A185. http://dx.doi.org/10.1093/sleep/zsab072.469.
Повний текст джерелаАнотація:
Abstract Introduction Habitual snoring has been associated with hypertensive disorders of pregnancy. However, exactly when blood pressure (BP) trajectories diverge between pregnant women with and without habitual snoring is unknown. Moreover, the potentially differential impact of chronic versus pregnancy-onset habitual snoring on maternal BP trajectories during pregnancy has not been examined. Methods In a cohort study of 1,305 pregnant women from a large Midwestern medical center, participants were asked about habitual snoring (≥3 nights/week) and whether their symptoms began prior to or during pregnancy. Demographic and BP data throughout pregnancy, systolic (SBP) and diastolic (DBP) were abstracted from medical charts. Linear mixed models were used to examine associations between habitual snoring-onset and pregnancy BP trajectories. Results Thirty percent of women reported snoring before pregnancy (chronic snoring) and an additional 23% reported pregnancy-onset snoring. Overall, women with pregnancy-onset snoring had higher mean SBP and DBP compared to those with chronic habitual snoring or controls (non-habitual snoring). In gestational week-specific comparisons with controls, SBP became significantly higher around 20 weeks’ gestation among women with pregnancy-onset snoring and in the third trimester among women with chronic snoring. Pairwise mean differences in DBP were significant only among women with pregnancy-onset snoring relative to controls, after 15 weeks’ gestation. Conclusion In a large cohort of pregnant women, those with pregnancy-onset or chronic habitual snoring had significantly elevated systolic BP in comparison to non-habitual snoring controls, in the second and third trimester, respectively. The findings of divergent BP trajectories suggest the two groups of women with habitual snoring in pregnancy should be considered separately when evaluating gestational ‘windows’ for increased BP monitoring and provide insight into pathophysiologic changes. Support (if any) Dr. Dunietz was supported by an F32 National Research Service Award from the National Institute of Child Health and Development (NIH/NICHD F32 HD091938); Dr. O’Brien was supported by the following during the course of this study: the Gene and Tubie Gilmore Fund for Sleep Research, the University of Michigan Institute for Clinical and Health Research (MICHR) grants UL1RR024986 and UL1TR000433, MICHR seed pilot grant F021024, the National Heart, Lung, and Blood Institute (R21 HL089918 and K23 HL095739) and in part by R21 HL087819.
7
Zhu, Jing, Jun Zhang, Mor Jack Ng, Bernard Chern, George SH Yeo, and Kok Hian Tan. "Angiogenic factors during pregnancy in Asian women with elevated blood pressure in early pregnancy and the risk of preeclampsia: a longitudinal cohort study." BMJ Open 9, no. 11 (November 2019): e032237. http://dx.doi.org/10.1136/bmjopen-2019-032237.
Повний текст джерелаАнотація:
ObjectiveIt remains unclear what roles placenta-originated angiogenic factors play in the pathogenesis of preeclampsia among hypertensive women. We compared maternal soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) levels throughout pregnancy in women with normal blood pressure (BP), elevated BP and hypertension in early pregnancy and their risks of developing preeclampsia.DesignA prospective cohort study.SettingKK Women’s and Children’s Hospital, Singapore.Participants923 women with singleton pregnancy <14 weeks of gestation were included in the prospective Neonatal and Obstetrics Risks Assessment cohort between September 2010 and October 2014. Systolic, diastolic, mean arterial blood pressure (MAP) were measured at 11–14 weeks.Primary and secondary outcomesMaternal serum sFlt-1, PlGF and sFlt-1/PlGF ratio were tested at 11–14, 18–22, 28–32 and 34 weeks onwards of gestation. Preeclampsia was main pregnancy outcome.ResultsWomen were divided based on their BP in early pregnancy: normal (n=750), elevated BP (n=98) and hypertension (n=75). Maternal sFlt-1 levels and sFlt-1/PlGF ratios were higher in hypertensive women throughout pregnancy, but maternal PlGF levels were not significantly lower. Rise in maternal systolic, diastolic BP and MAP at 11–14 weeks were significantly associated with higher sFlt-1/PlGF ratios during pregnancy. A 10 mm Hg increase in MAP was associated with a 5.6-fold increase in risk of preterm preeclampsia and a 3.3-fold increase in risk of term preeclampsia, respectively.ConclusionWomen with elevated BP in early pregnancy already had a higher sFlt-1/PlGF ratio in early gestation and throughout pregnancy, and an increased risk of preeclampsia. In contrast, PlGF levels in these women remained normal.
8
Dougall, Greig, Marloes Franssen, Katherine Louise Tucker, Ly-Mee Yu, Lisa Hinton, Oliver Rivero-Arias, Lucy Abel, et al. "Blood pressure monitoring in high-risk pregnancy to improve the detection and monitoring of hypertension (the BUMP 1 and 2 trials): protocol for two linked randomised controlled trials." BMJ Open 10, no. 1 (January 2020): e034593. http://dx.doi.org/10.1136/bmjopen-2019-034593.
Повний текст джерелаАнотація:
IntroductionSelf-monitoring of blood pressure (BP) in pregnancy could improve the detection and management of pregnancy hypertension, while also empowering and engaging women in their own care. Two linked trials aim to evaluate whether BP self-monitoring in pregnancy improves the detection of raised BP during higher risk pregnancies (BUMP 1) and whether self-monitoring reduces systolic BP during hypertensive pregnancy (BUMP 2).Methods and analysesBoth are multicentre, non-masked, parallel group, randomised controlled trials. Participants will be randomised to self-monitoring with telemonitoring or usual care. BUMP 1 will recruit a minimum of 2262 pregnant women at higher risk of pregnancy hypertension and BUMP 2 will recruit a minimum of 512 pregnant women with either gestational or chronic hypertension. The BUMP 1 primary outcome is the time to the first recording of raised BP by a healthcare professional. The BUMP 2 primary outcome is mean systolic BP between baseline and delivery recorded by healthcare professionals. Other outcomes will include maternal and perinatal outcomes, quality of life and adverse events. An economic evaluation of BP self-monitoring in addition to usual care compared with usual care alone will be assessed across both study populations within trial and with modelling to estimate long-term cost-effectiveness. A linked process evaluation will combine quantitative and qualitative data to examine how BP self-monitoring in pregnancy is implemented and accepted in both daily life and routine clinical practice.Ethics and disseminationThe trials have been approved by a Research Ethics Committee (17/WM/0241) and relevant research authorities. They will be published in peer-reviewed journals and presented at national and international conferences. If shown to be effective, BP self-monitoring would be applicable to a large population of pregnant women.Trial registration numberNCT03334149
9
Alabeidi, Fahad, Faisal Mohammed Alosaimi, Sarah Abdullah Alsaeed, Ibrahim Furih Alshammari, Mohammed Hamdan Al Shamry, Abdulelah Mohammed Mubashir Alamri, Mohammad Raja Aljehani, et al. "Home monitoring of blood pressure in children, pregnancy, and chronic kidney diseases via personal blood pressure meters- An updated review for pharmacists." International journal of health sciences 4, S1 (January 8, 2020): 320–31. http://dx.doi.org/10.53730/ijhs.v4ns1.15263.
Повний текст джерелаАнотація:
Background: Blood pressure (BP) monitoring is critical in managing hypertension across various populations, including children, pregnant women, and patients with chronic kidney disease (CKD). Traditional clinic-based BP measurements often lead to misdiagnoses due to white-coat and masked hypertension. Aim: This review highlights the significance of home BP monitoring in children, pregnancy, and CKD, evaluating its accuracy, practicality, and integration into clinical practice. Methods: A literature review was conducted, analyzing studies on home BP monitoring across pediatric, pregnancy, and CKD populations. Data on oscillometric devices and validation studies were included. Results: Home BP monitoring is increasingly used in pediatric hypertension, with an 80–85% agreement with ambulatory monitoring. In pregnancy, home monitoring aids in detecting preeclampsia and helps maintain optimal BP levels. For CKD, home BP readings are superior to clinical measurements, accurately predicting disease progression and cardiovascular risk. Conclusion: Home BP monitoring proves valuable in managing hypertension across vulnerable populations, offering convenience, reliability, and better diagnostic precision. Further research is needed to refine device accuracy and integrate home monitoring into routine care for children, pregnant women, and CKD patients.
10
Shim, Soon-Sup, Jong Kwan Jun, Joong Shin Park, Yoon-Mi Hur, Young Min Choi, Bo Hyun Yoon, and Hee Chul Syn. "Angiotensinogen G(–6)A Polymorphism Is Associated With the Elevation of Blood Pressure in the Hypertensive Disorders of Pregnancy." Twin Research and Human Genetics 9, no. 1 (February 1, 2006): 76–80. http://dx.doi.org/10.1375/twin.9.1.76.
Повний текст джерелаАнотація:
AbstractThe objective of the present study was to determine whether angiotensinogen G(–6)A polymorphism is associated with the elevation of blood pressure (BP) in the hypertensive disorders of pregnancy in Korean population. The subjects included 201 cases with the hypertensive disorders of pregnancy and 160 healthy controls. The medical records of subjects were reviewed. Cases were classified into the four subtypes (transient hypertension, preeclampsia, chronic hypertension, and preeclampsia superimposed on chronic hypertension) by the diagnostic criteria suggested by the National High Blood Pressure Education Program Working Group. Cases were also divided into the high and low BP group by the elevation of BP (diastolic BP greater than or equal to 110 mmHg). Maternal angiotensinogen G(–6)A polymorphism was determined by restriction fragment length polymorphism. Frequencies of AA genotype were significantly higher in the high than in the low BP group in the preeclampsia, superimposed preeclampsia, and the combined group (N = 201), suggesting that the angiotensinogen G(–6)A allele was significantly associated with the elevation of BP in the hypertensive disorders of pregnancy among South Korean women. The present findings imply that the elevation of BP can serve as an endophenotype for a spectrum of hypertensive conditions in pregnancy.
Частини книг з теми "Pregnancy BP"
1
McCarthy, Fergus. "Hypertension in pregnancy." In Oxford Textbook of Medicine, edited by Catherine Nelson-Piercy, 2583–88. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0266.
Повний текст джерелаАнотація:
High blood pressure (BP >140/90 mm Hg) complicates approximately 10% of pregnancies and may be due to white coat hypertension, chronic hypertension, gestational hypertension, or pre-eclampsia (de novo or superimposed on chronic hypertension). Pre-eclampsia occurs in 2–8% of pregnancies and remains a common cause of fetal and maternal death in developing countries. Maternal symptoms include headache/visual disturbances, breathlessness, epigastric pain, and seizures (eclampsia); signs include pulmonary oedema, liver tenderness, hyper-reflexia/clonus, and papilloedema. Treatment of pre-eclampsia is by timely delivery of the fetus (and placenta) to minimize maternal complications and maximize fetal gestational age, while avoiding morbidity and mortality. Pharmacological treatment to control hypertension is generally given when BP consistently exceeds 150 mm Hg (systolic) or 90 mm Hg (diastolic). Commonly used agents include labetalol, nifedipine, amlodipine, and α-methyldopa. ACEi, ARBs, and diuretics should not be used in pregnancy. Intravenous magnesium sulphate is given to women at risk of eclampsia.
2
Mrcp, D. J. Williams. "Pre-eclampsia." In Critical Care Cases, 205–8. Oxford University PressNew York, NY, 1997. http://dx.doi.org/10.1093/oso/9780192625847.003.0045.
Повний текст джерелаАнотація:
Abstract A 19-year-old primigravida booked in for antenatalcare at 14 weeks gestation. BP was 100/65 mmHg and there was no significant past medical history. Her pregnancy progressed uneventfully until 28 weeks when .she was admitted from a routine antenatal clinic with a BP of 155/100 mmHg, +++ proteinuria, but no peripheral oedema
3
Konkov, Dmytro, George Belkania, Levon Dilenyan, Victor Rud, Liana Puchalska, Alina Piskun, and Larisa Klimas. "Gestational Endotheliopathy as Trigger Disorder of Haemodynamics Pregnancy Supply." In Preeclampsia. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.100737.
Повний текст джерелаАнотація:
The idea for this study is based on endothelial-dependent adaptation of hemodynamic circulation in pregnancy. The optimization of the circulatory component of the cardiovascular system (CVS) during pregnancy via blood pressure (BP), especially in physiological pregnancy (PhP), is accompanied by a clear overall increase in systolic characteristics of the pumping function of the heart. This orientation in cardiac output (CO) is unambiguously manifested throughout all three trimesters as with PhP—in a prone and standing position in total according to 24 characteristics out of 24 (P < 0.01), while for gestational endotheliopathy (PaP)—by 18 out of 24 (P < 0.05) clear restructuring of the dynamic organization of the circulatory state according to the anthropophysiological ratio to the hyperkinetic state according to CO in a standing position (type III) was noted with all blood pressure (BP) regimes. If the manifestation of type III under hypotonic, normotonic, and hypertonic regimes in BP was 8, 12, and 6%, respectively, then in the case of PhP, it was 21, 36, and 50%, respectively (P < 0.01), and for PaP, it was 48, 66, and 76% (P < 0.01). Hemodynamically identified heart failure (HF) syndrome, as the earliest preclinical circulatory endothelial-dependent form, is examined as a trigger of formation of perinatal pathology corresponding to preeclampsia.
4
Devi, K. Renuka. "Prediction of Preeclampsia in Pregnant Women Using Machine Learning Paradigm." In Predicting Pregnancy Complications Through Artificial Intelligence and Machine Learning, 140–61. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-6684-8974-1.ch010.
Повний текст джерелаАнотація:
Machine learning is an area that helps to predict outcomes more accurately. It was utilized in different domains such as banking, healthcare, education, etc. Among all the domains, machine learning was largely utilized in the healthcare sector for predicting and diagnosing the disease in advance for saving millions of lives. ML has different kinds of algorithms which help to make the prediction process effective. This chapter focussed on explaining different machine learning algorithms for making better predictions in pregnancy complications in the healthcare domain. In general, there are different complications that women encountered during their pregnancy periods such as High BP, preeclampsia, anemia, etc. This work specifically aims to describe the preeclampsia complication during pregnancy. In machine learning, various kinds of regression algorithms are compared and analyzed. It also focused on which predictive technique would be more efficient for predicting the condition of preeclampsia in advance to save lives of pregnant women and also take necessary precautions.
5
Frise, Charlotte, Krupa Bhalsod, Rebecca Scott, and Harry Gibson. "Case 42." In Oxford Case Histories in Obstetric Medicine, 277—C42P43. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780192845894.003.0042.
Повний текст джерелаАнотація:
Abstract A 34-year-old woman underwent IVF treatment and became pregnant with DCDA twins. At booking her BP was 117/70 mmHg and her BMI was 28 kg/m2. Her pregnancy had been uncomplicated until the diagnosis of gestational diabetes, diagnosed on oral glucose tolerance test at 28 weeks. She was managing her blood glucose levels by dietary changes alone. She presented to the assessment unit at 34 weeks of gestation feeling generally unwell, with symptoms of nausea, alongside new-onset polyuria and polydipsia. She had no past medical history and was not on any regular medication. She was a non-smoker.
6
Frise, Charlotte, Krupa Bhalsod, Rebecca Scott, and Harry Gibson. "Case 3." In Oxford Case Histories in Obstetric Medicine, 13—C3P40. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780192845894.003.0003.
Повний текст джерелаАнотація:
Abstract A 28-year-old woman with no known medical problems presented with a 9-day history of a non-productive cough, shortness of breath, fever, headache, and loss of smell and taste. She was 35 weeks into her first pregnancy. She had not been abroad recently. She lived with her husband and his parents, and all had developed similar symptoms in the preceding few days. Her booking BP was 110/80 mmHg and BMI was 30 kg/m2. She was not on any regular medication, there was no family history of medical problems, and she had never smoked. She was of Indian ethnicity and had decided not to be vaccinated against SARS-CoV2 whilst she was pregnant.
7
Frise, Charlotte, Krupa Bhalsod, Rebecca Scott, and Harry Gibson. "Case 1." In Oxford Case Histories in Obstetric Medicine, 1—C1P42. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780192845894.003.0001.
Повний текст джерелаАнотація:
Abstract A 23-year-old woman in her first pregnancy presented at 32 weeks of gestation with a 1-day history of progressively worsening, constant, lower thoracic and upper lumbar back pain. There was no history of trauma or heavy lifting, and no symptoms of urinary retention, faecal incontinence, or neurological symptoms in the lower limbs. Her pregnancy had been uncomplicated prior to this. At booking her BMI was normal and her BP was 95/70 mmHg. She had a past medical history of hypermobility. Her family history included hypertension in her father, and her sister had a history of spontaneous bowel perforation. She was a non-smoker.
8
Ffarcs, G. C. Hanson Frcp. "Haemolysis, elevated liver enzymes, and low platelets (HELLP)." In Critical Care Cases, 193–98. Oxford University PressNew York, NY, 1997. http://dx.doi.org/10.1093/oso/9780192625847.003.0043.
Повний текст джерелаАнотація:
Abstract A white female ageo 36 years, with two previous pregnancies both complicated by hypertension towards term, was admitted at 28 weeks pregnancy with a 3-day history of malaise, nausea, and epigastric pain. On admission she had minimal facial and ankle oedema; BP was 160/90 mmHg. There was minimal tenderness in the right hypochondrium. Over the next 3 days the patient deteriorated with increasing oedema, theonset of a headache with irritability, and development of haematuria. She then developed sudden hypotension, tachycardia, and oliguria.
9
Frise, Charlotte, Krupa Bhalsod, Rebecca Scott, and Harry Gibson. "Case 16." In Oxford Case Histories in Obstetric Medicine, 97—C16P60. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780192845894.003.0016.
Повний текст джерелаАнотація:
Abstract A 25-year-old woman attended her 16-week antenatal appointment with her midwife and mentioned she had developed intermittent pain affecting the small joints of both hands and wrists 10 months prior to this appointment, but they had become more problematic in the preceding 5 weeks. In addition, she had developed a facial rash, intermittent chest discomfort, and shortness of breath. This was her first pregnancy. Her booking BP was 117/70 mmHg and BMI was 27 kg/m2. She took no medication, and she had no significant past medical history or family history. She did not smoke or drink alcohol. She was referred for urgent review.
10
Frise, Charlotte, Krupa Bhalsod, Rebecca Scott, and Harry Gibson. "Case 12." In Oxford Case Histories in Obstetric Medicine, 71–78. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780192845894.003.0012.
Повний текст джерелаАнотація:
Abstract A 20-year-old woman presented at 28 weeks of gestation in her first pregnancy with a 2-week history of palpitations. They were occurring daily, lasting for 10–15 minutes, and usually occurred at rest. There was no associated chest pain, shortness of breath, or syncope. She had had no previous episodes and was otherwise fit and well, with no significant past medical history. She was not on any regular medication, and she had never smoked. Her booking BP was 100/70 mmHg and BMI was 24 kg/m2. On examination observations were normal apart from a heart rate of 110 bpm.
Тези доповідей конференцій з теми "Pregnancy BP"
1
van den Heuvel, Robert. "Post-partum intervention lowers BP after hypertensive pregnancy." In AHA Scientific Sessions 2023, edited by Marc Bonaca. Baarn, the Netherlands: Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/44b11740.
Повний текст джерела
2
GRUEL, Y., P. MOALIC, E. DUROUCHET, C. GUEROIS, B. DELAHOUSSE, and J. LEROY. "LEVELS OF TOTAL AND FREE PROTEIN S DURING NORMAL AND PATHOLOGICAL PREGNANCY AND IN POST-PARTUM." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644281.
Повний текст джерелаАнотація:
Levels of total and free Protein S (PS) were measured on plasmas from 28 women during normal (n = 15, mean age = 25) and pathological pregnancy (Hypertension or preeclampsia, n = 13, mean age = 27). Prepartum (PreP) samples were obtained in the third trimester between the 30th and the 40th weeks of gestation, and postpartum (PostP) blood collected in the 5 days after delivery. Total PS level was determined using Laurel 1 rocket immunoelectrophoresis (Diagnostica Stago, Asnifcres-France). Free PS was measured using the same method after precipitation of C4b-BP-Bound-PS by polyethylene glycol. C4b-Binding Protein (C4b-BP) determinations were conducted by Laurel 1 method as well. Results were expressed as a percentage (Mean ± SD) of a normal adult pool (n = 15).A significant decrease of free PS level was observed both in normal or pathological pregnancy and in postpartum. These data might be explained, by the increase of C4b-BP plasmatic level.*= p<0.05 (as compared to normal controls), **= p<0.01, ***= p<0.001 (Student´s t test).
3
Panyarath, P., N. Goldscher Minerbi, S. Pamidi, R. Gagnon, S. Daskalopoulou, N. Dayan, K. Raiche, A. Olha, A. Benedetti, and R. J. Kimoff. "Effect of Maternal Obstructive Sleep Apnea-Hypopnea (OSAH) on 24-Hour Blood Pressure (BP) in Hypertensive Disorders of Pregnancy (HDP)." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2528.
Повний текст джерела
4
Wang, Lu, and Dianzhong Wen. "BP Neural Network to Distinguish Pregnant Woman by Arterial Pressure Pulse Waveform Analysis." In 2008 Fourth International Conference on Intelligent Information Hiding and Multimedia Signal Processing (IIH-MSP). IEEE, 2008. http://dx.doi.org/10.1109/iih-msp.2008.253.
Повний текст джерелаЗвіти організацій з теми "Pregnancy BP"
1
Steele, Dale W., Gaelen P. Adam, Ian J. Saldanha, Ghid Kanaan, Michael L. Zahradnik, Valery A. Danilack, Alison M. Stuebe, Alex Friedman Peahl, Kenneth K. Chen, and Ethan M. Balk. Management of Postpartum Hypertensive Disorders of Pregnancy. Agency for Healthcare Research and Quality (AHRQ), May 2023. http://dx.doi.org/10.23970/ahrqepccer263.
Повний текст джерелаАнотація:
Background. Hypertensive disorders of pregnancy (HDP) are increasingly common and have important implications for maternal health, healthcare utilization, and health disparities. There is limited evidence to support best management of postpartum individuals with HDP, including home blood pressure (BP) monitoring (HBPM) and choice of antihypertensive agents. For patients experiencing preeclampsia with severe features, there is robust evidence supporting delivery of the infant and treatment with magnesium sulfate (MgSO4). However, MgSO4 may cause unpleasant side effects and, less commonly, toxicity. Patients receiving MgSO4 require additional monitoring (e.g., urinary catheterization) and often have activity restrictions, which impact their postpartum experience. Evidence regarding the optimal (lowest effective) dose and (shortest effective) duration of MgSO4 treatment is needed. Methods. We searched Medline®, Cochrane, Embase®, CINAHL®, and ClinicalTrials.gov from inception to December 1, 2022. After double screening, we extracted study data and risk of bias assessments into the Systematic Review Data Repository Plus (SRDR+; https://srdrplus.ahrq.gov). We evaluated the strength of evidence (SoE) using standard methods. The protocol was registered in PROSPERO (registration number CRD42022313075). Results. We found 13 eligible studies (3 randomized controlled trials [RCTs], 2 nonrandomized comparative studies [NRCSs], 8 single-arm studies) evaluating postpartum HBPM, 17 RCTs evaluating pharmacological treatment of postpartum HDP, and 43 studies (41 RCTs and 2 NRCSs) that compared alternative MgSO4 regimens. HBPM programs probably increase submission of any BP measurements during recommended time intervals (moderate SoE) and may increase the number of BP measurements obtained overall (low SoE). Studies have not found that HBPM affects the rate of BP treatment initiation (low SoE), but HBPM may reduce unplanned hypertension-related hospital admissions (low SoE). Most patients were satisfied with management related to HBPM (low SoE), and HBPM probably compensates for racial disparities in office-based follow-up (moderate SoE). In patients with preeclampsia or gestational hypertension (HTN), oral furosemide may shorten the duration of postpartum hypertension (low SoE). There was insufficient evidence regarding the comparative benefits and harms of other antihypertensive medications. Compared with 24-hour treatments, shorter duration MgSO4 regimens shorten the urinary catheterization time (high SoE), time to ambulation (high SoE), and time to breastfeeding (moderate SoE); and may shorten time from delivery to contact with the infant and decrease toxicity as manifested by lost deep tendon reflexes (both low SoE). Loading dose only regimens increase the risk of a recurrent seizure in patients with eclampsia (moderate SoE). Lower dose MgSO4 regimens, compared to standard dose regimens, reduce early signs of magnesium toxicity (high SoE), may approximately double the risk of recurrent seizure in patients with eclampsia (low SoE), but may not affect 5-minute Apgar scores in infants of patients with preeclampsia with severe features (low SoE). There is insufficient evidence regarding potential harms of concomitant use of nifedipine or other antihypertensive medications. Conclusion. HBPM probably improves ascertainment of BP, allowing early recognition of hypertension in postpartum patients, and probably compensates for racial disparities in office based follow-up. The evidence suggests furosemide may shorten the duration of postpartum HTN. However, further evidence is needed regarding the comparative benefits and harms of the antihypertensive medications used to treat postpartum HTN. Large pragmatic trials, augmented by analysis of real-world data, are needed to evaluate the effect of postpartum HBPM on clinical event outcomes (not only process outcomes) and on the comparative effectiveness of alternative antihypertensive treatments. Given that lower dose MgSO4 regimens reduce Mg toxicity, and shorter regimens decrease urinary catheterization time, time to ambulation, time to breastfeeding, and time from delivery to contact with the infant, evidence is needed to identify MgSO4 regimens with the lowest effective dose and shortest effective duration that minimize side effects and toxicity but still prevent seizures among patients with preeclampsia with severe features.